Dean's List: New Funding Awards 2023

2023

Notable & novel scientific awards to celebrate.

December 2023 New Federal Awards:
Sanjana Dayal	Internal Medicine	NIH R01 4 years	Preventive mechanisms of Age-associated Thrombosis
John Fingert, Contact PI Todd Scheetz, MPI Budd Tucker, MPI	Ophthalmology	NIH R21 2 years	Stem cell approaches to normal tension glaucoma
Robert Piper, Contact PI Chris Anern, MPI	Physiology	NIH R33 2 years	Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit Function
Eric Taylor	Physiology	NIH R01 4 years	Regulation of Hepatic Fuel Fluxes by the Mitochondrial Dicarboxylate Carrier
Mary Weber	Microbiology	NIH R61 3 years	Development of genetic tools for overexpression and targeted mutagenesis of Orientia tsutsugamushi TPR proteins
Competitive Awards:
Enrique Leira	Neurology	NIH U24 5 years	The University of Iowa's Regional Stroke Research Network
Other Awards:
Stephanie Chen	Pathology	Exact Sciences Corporation 3 years	Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
Nabeel Hamzeh	Internal Medicine	Bristol-Myers Squibb Company 3 years	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Markus Kuehn	Ophthamology	Animal Eye Consultants of Iowa 2 years	Adaptive Immune Responses Contributing to Canine Glaucoma
Delwyn Miller	Psychiatry	University of Southern California 5 years	Alzheimer's Disease Neuroimaging Initiative (ADNI4)
Amy Ryan	Anatomy and Cell Biology	Children's Hospital of Los Angeles 1 year	Development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19
Michael willey	Orthopedics	MEND Nutrition, Inc. 3 years	MENDTM Clinical Trial Proposal
November 2023 New Federal Awards:
Yi Huang	Internal Medicine	NIH R01 3 years	Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response
Competitive Awards:
Stanley Perlman	Microbiology	NIH R01 5 years	Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response
Other Awards:
Umar Farooq	Internal Medicine	Cargo Therapeutics 5 years	An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CART-cell
Umar Farooq	Internal Medicine	Janssen Research & Development, Inc. 4 years	A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma
Philip Gander, Contact PI Joel Berger MPI	Radiology, Neurosurgery	REAM Foundation, 2 years	Novel Investigation of Brain Mechanisms for Different Triggers in Misophonia
Dilek Ince	Internal Medicine	Corixa Corporation 3 years	A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an
Annie Killoran	Nurology	Genetech, Inc. 3 years	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study To Evaluate The Safety, Biomarkers, And Efficacy Of Tominersen In Individuals With Prodromal And Early Manifest Huntington's Disease
Douglas Laux	Internal Medicine	Replimune, Ltd. 3 years	A Phase 2, Open-label, Multicenter Study Investigating RP3 in Combination with Other Therapy in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Douglas Laux	Internal Medicine	Seagen, Inc. 3 years	A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors
Mohammed Milhem	Internal Medicine	Seagen, Inc. 3 years	A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors
Sneha Phadke	Internal Medicine	AstraZeneca Pharmaceuticals LP 3 years	A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/
Chen Tan	Internal Medicine	Ansun Biopharma, Inc. 3 years	A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parain:fluenza Infection in Immunocompromised Subjects
Yousef Zakharia	Internal Medicine	Worldwide Clinical Trials, Inc. 3 years	A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS
October 2023 New Federal Awards:
James Byrne	Radiation Oncology	NIH K08 5 years	Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel
Grace Ciampa	Internal Medicine	NIH F31 2 years	Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex
Competitive Awards:
Thomas Scholz	Pediatrics	Iowa Department of Human Services 1 year	MHDS 24-008 Community Circle of Care
Kirill Nourski	Neurosurgery	University of Wisconsin-Madison 4 years	Mechanisms of Loss, Recovery and Disorders of Consciousness
Other Awards:
Ernesto Ruiz Duque	Internal Medicine	Bristol-Myers Squibb Company 3 years	DISCOVER-HCM
Rami El Abiad	Internal Medicine	Celldex Therapeutics, Inc. 3 years	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis
Andrew Russo	Molecular Physics & Biophysicis	Seattle Institute for Biomedical and Clinical Research 5 years	Role of Sleep Disruption after mTBI as a Driver of Chronic Post-Traumatic Headache
Alejandro Comellas Freymond	Internal Medicine	IQVIA RDS Inc. 3 years	A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Muhammad Furqan	Internal Medicine	AbbVie, Inc. 3 years	A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.
Muhammad Furqan	Internal Medicine	BeiGene USA 3 years	A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Muhammad Furqan	Internal Medicine	Poseida Therapeutics, Inc. 3 years	A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
David Axelrod	Surgery	CTI Clinical Trial Services, Inc. 3 years	An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standa
Sneha Phadke	Internal Medicine	NSABP Foundation, Inc. 5 years	CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or
Carla Nester	Pediatrics	Apellis Pharmaceuticals, Inc. 3 years	AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Patrick Sinn	Pediatrics	Cystic Fibrosis Foundation 2 years	005661G223 Base-Editing for Life-Long Correction of CF Airways
Vishnu Mani	Surgery	Direct Biologics, LLC 3 years	Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients with Moderate-to-Severe ARDS: A Phase III Clinical Trial
Eric Hoffman	Radiology	Imperial College London 2 years	THE BLF EARLY COPD DEVELOPMENT PARTNERSHIP GRANT
Brian Link	Internal Medicine	Mayo Clinic 3 years	Characteristics and outcomes of patients with Diffuse Large B-cell Lymphoma Receiving Frontline Treatment at Cancer Centers within the LEO Cohort, ML43785
September 2023 New Federal Awards:
John Fingert, Contact PI Todd Scheetz, MPI	Ophthalmology	NIH R01 5 years	Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism
Aloysius Klingelhutz	Microbiology	NIH R21 2 years	The role of ISG15 and ISGylation in the senescence-associated secretory phenotype
Elizabeth Newell	Pediatrics	NIH R01 5 years	Mechanisms of type I interferon neuropathology following traumatic brain injury
Jon Houtman	Microbiology	NIH R25 5 years	R25 YES: Cancer Research Opportunities at Iowa
Competitive Awards:
Milan Sonka, Contact PI John Buatti, MPI	Radiation Oncology	NIH R56 1 year	Deep LOGISMOS
Vincent Magnotta, Contact PI John Wemmie, MPI	Radiology, Psychiatry	NIH R01 5 years	Cerebellar metabolism, neural circuits, and symptoms in bipolar disorder
Other Awards:
Umar Farooq	Internal Medicine	Angiocrine Bioscience, Inc. 3 years	Angiocrine Long Term Follow-Up Umbrella Study
Umar Farooq	Internal Medicine	Nektar Therapeutics 3 years	A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Bruce Gantz	Otolaryngology	Cochlear Americas 3 years	Preliminary Evaluation of a Dexamethasone Eluting Electrode Array
Marlan Hansen	Otolaryngology	Julius Clinical Research B.V. 3 years	A Natural History Study in Individuals with Otoferlin Gene (OTOF)-Mediated Hearing Loss
Annie Killoran	Neurology	Worldwide Clinical Trials, Inc. 3 years	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (G
Antonio Sanchez	Internal Medicine	Merck Sharp & Dohme LLC 3 years	A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis
Antonio Sanchez	Internal Medicine	PPD Investigator Services, LLC 3 years	A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Christopher Strouse	Internal Medicine	Poseida Therapeutics, Inc. 3 years	Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM)
August 2023 New Federal Award:
Alexander Boyden	Pathology	NIH R01 5 years	Pathogenic B cell:CD4 T cell interactions in a novel B cell-dependent EAE mouse model of multiple sclerosis
Sean Fain	Radiology	NIH R01 5 years	Dynamic Imaging of Lung Ventilation and Perfusion Using CT and MRI
Gena Ghearing	Neurology	CDC 5 years	Expanding epilepsy self-management support in healthcare networks (EXPAND)
Aleksander Lenert	Internal Medicine	NIH K23 3 years	Investigating Disease Activity, Bone Damage and Interleukin-1 Genes in Adult SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis
Yi Luo	Urology	DOD, CDMRP 4 years	CP220038 - Development of a novel DNA aptamer-based IFN-y targeted therapy for chronic cystitis pain
Wendy Maury, Contact PI Noah Butler, MPI	Microbiology	NIH UH2 2 years	Defining the effect of Plasmodium infection on Ebola virus vaccine efficacy
Ben Miskle	Pharmacy Practice and Science (Award in Psychiatry)	SAMHSA H79 5 years	Iowa Naloxone Expansion and Training (IA-NEXT)
Catherina Pinnaro	Pediatrics	NIH K23 3 years	Hyperglycemia in Turner syndrome: Mechanisms and X chromosome contributions
Matthew Potthoff	Neuroscience & Pharmacology	NIH R01 5 years	Therapeutic Potential of FGF21 for Alzheimer's Disease
Brett Faine, Contact PI David Talan, MPI	Emergency Medicine	NIH R21 2 years	Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
Seth Tomchik	Neuroscience & Pharmacology	NIH R01 2 years	Dopaminergic circuit modulation of learning and arousal-mediated memory enhancement
Elliott Sohn, Contact PI Jon Houtman, MPI Milan Sonka, MPI	Ophthalmology, Microbiology, Electrical & Computer Engineering	NIH R01 4 years	MMP-9 based immune-driven mechanisms of neovascular AMD
Competitive Awards:
Marlan Hansen, Contact PI C. Guymon, MPI	Otolaryngology	NIH R01 5 years	Reduction of Intracochlear Trauma and Fibrosis Using Dual Network, Zwitterionic Hydrogel Thin Films on Cochlear Implant Surfaces
Robert Mullins, Contact PI Budd Tucker, MPI	Ophthlamology	NIH R01 4 years	Choriocapillaris Protection and Replacement in AMD
Other Awards:
David Bender	OBGyn	GOG Foundation 3 years	Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube,
James Byrne	Radiation Oncology	V Foundation for Cancer Research 3 years	Overcoming immunotherapy resistance using oxygen-entrapping materials
Marcelo Correia	Internal Medicine	Lilly USA, LLC 3 years	A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
Umar Farooq	Internal Medicine	ImmPACT Bio USA Inc. 3 years	A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IMPT-314, A CD19/20 BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Muhammad Furqan	Internal Medicine	AGRESSIVE B-CELL NON HODGKIN LYMPHOMA 3 years	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304)
Muhammad Furqan	Internal Medicine	Elicio Therapeutics, Inc. 3 years	First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors
Hillel Haim	Microbiology	ViiV Healthcare 5 years	Computational platform to personalize Fostemsavir treatment to people living with HIV-1
Asad Javed	Internal Medicine	Lyell Immunopharma, Inc. 3 years	A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Mohammed Milhem	Internal Medicine	Merck Sharp & Dohme LLC 8 years	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010)
Sneha Phadke	Internal Medicine	Arvinas Estrogen Receptor Inc. 3 years	An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting
Philip Polgreen	Internal Medicine	Pfizer, Inc 4 months	Developing approaches to estimate a more accurate measure of the burden of influenza
Ernesto Ruiz Duque	Internal Medicine	Bristol-Myers Squibb Company 3 years	ODYSSEY-HCM
Lucy Wibbenmeyer	Surgery	PolyNovo Biomaterials Pty Ltd. 3 years	Pivotal Study to Assess the Safety and Effectiveness of NovoSorb Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries
July 2023 New Federal Awards:
Alexandra Bova	Neurology	NIH F32 1 year	Nigrostriatal dopamine mechanisms of cognitive control
Martine Dunnwald	Anatomy & Cell Biology	NIH R03 1 year	Popliteal Pterygium syndrome, IRf6, and the periderm
Adam Dupuy	Anatomy & Cell Biology	US DoD, CDMRP HT9425-23-1-0780 3 years	ME220036 Identification of genetic mechanisms driving transition of benign nevi to malignant melanoma
Oliver Gramlich	Ophthlamology	NIH R03 5 years	Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis
Xiaoyang Hua	Otolaryngology	NIH R01 5 years	The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations
Miles Pufall	Biochemistry & Molecular Biology	US National Science Foundation 2324615 3 years	NSF/MCB-BSF: The effect of transcription factor binding on UV lesion accumulations
Chen Tan	Internal Medicine	NIH R01 2 years	NK cell responses to JC polyomavirus
Tomohiro Tanaka	Internal Medicine	US DoD, CDMRP k08 5 years	Estimating the Causal Effect of Liver Allocation Policy Reflecting the Heterogeneity from Age and Geography
Kristina Thiel	OBGyn	US DoD, CDMRP HT9425-23-1-0744 4 years	CA220729P1 - Progestin therapy for endometrial cancer
Other Awards:
Loreen Herwaldt	Internal Medicine	University of Wisconsin-Madison 2 years	Povidone-iodine to Stop Access-Related Infections and Transmission of Staphylococcus Aureus (PAINTS)
Katie Larson Ode	Pediatrics	Worldwide Clinical Trials, Inc. 3 years	A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity
Kelly Mulfaul	Ophthalmology	BrightFocus Foundation 3 years	Investigating Human Choroidal Macrophage Recruitment and Activation in Age-related Macular Degeneration - Mulfaul 2022 - BrightFocus
Sneha Phadke	Internal Medicine	Olema Pharmaceuticals, Inc. 3 years	A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer
Donna Santillan, Contact PI Mark santillan, MPI	OBGyn	Heartland Health Research Alliance, LTD 3 years	Heartland
Tomohiro Tanaka	Internal Medicine	PPD Investigator Services, LLC 3 years	Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1)
George Weiner	Internal Medicine	V Foundation for Cancer Research 4 years	T cell help and resistance to anti-cancer monoclonal antibody therapy
Yousef Zakharia	Internal Medicine	Astellas Pharma Global Development, Inc. 3 years	A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors
Yousef Zakharia	Internal Medicine	AstraZeneca LP 3 years	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients I
June 2023 New Federal Awards:
Marina Del Rios	Emergency Medicine	NIH R01 4 years	Dime la VerDAD - Verify, Debunk, and Disseminate
Joel Geerling	Neurology	NIH R01 5 years	Brainstem cold-defense circuitry
Corinne Griguer	Radiation Oncology	NIH R01 5 years	Mitochondria electron transport chain complexes adaptative responses to cellular stress
John Harty	Pathology	NIH R21 2 years	Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS
Diana Jalal, Contact PI Richard Smith, MPI	Internal Medicine, Otolaryngology	NIH R01 5 years	The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD
Benjamin Kelvington	Neuroscience & Pharmacology	NIH F31 3 years	Defining the molecular impact of 16p11.2 deletion on reward response in striatal dopamine receptor D1-expressing neurons
Scott Lieberman	Pediatrics	NIH R01 5 years	Tyk2 and Associated Cytokines in Salivary Gland Autoimmunity
Allison Momany	Pediatrics	NIH K99 2 years	Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment
Andrew Sullivan	Neuroscience & Pharmacology	NIH F31 3 years	The Role of IRX3 Neurons in the Regulation of Body Weight Homeostasis
Other Awards:
Ted Abel	Neuroscience & Pharmacology	George Mason University 5 years	Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity
Sabarish Ayyappan	Internal Medicine	Mayo Clinic 3 years	Randomized phase 2 study with safety run-in of PD-1 inhibitor and IgG4 SIRP-Fc fusion protein (TTI-622) and PD-1 inhibitor and IgG1 SIRP-Fc fusion protein (TTI-621) in relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Chandrikha Chandrasekharan	Internal Medicine	Astellas Pharma, Inc 3 years	A Phase 1/1b study of ASP2074 in participants with Metastatic or Locally Advanced solid tumors
Rami El Abiad	Internal Medicine	Ellodi Pharmaceuticals, L.P. 3 years	Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic
Muhammad Furqan	Internal Medicine	Tempus Labs, Inc. 3 years	TEMPUS GEMINI NSCLC SURVEILLANCE STUDY
Jeremy Greenlee	Neurosurgery	Massachusetts Eye & Ear Infirmary	Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor, Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor (Project 3)
Serena Gumusoglu	OBGyn	Burroughs Wellcome Fund 4 years	Next Gen Pregnancy Initiative
Patrick McGonagill	Surgery	CSL Behring LLC 3 years	CSL Behring TAP Study
Jacob Michaelson	Psychiatry	Columbia University 1 year	Triangulation of missense variant impact through multimodal modeling and functional assays
Sneha Phadke	Internal Medicine	PSI Pharma Support America, Inc. 3 years	An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA)
Andrea Swenson	Neurology	Massachusetts General Hospital 2 years	An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis
Richard Tyler	Otolaryngology	Sage Therapeutics, Inc. 3 years	AN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF BREXANOLONE IN THE TREATMENT OF ADULT PARTICIPANTS WITH TINNITUS
May 2023 New Federal Awards:
Bryan Allan, Contact PI John Buatti, MPI	Radiation Oncology	NIH R21 2 years	Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial
Polly Ferguson, Contact PI Alaxander Bassuk, MPI	Pediatrics	NIH K12 5 years	CTSA K12 PROGRAM AT THE UNIVERSITY OF IOWA
Donna Santillan	ObGyn	NIH R25 5 years	Beginning and Early Stage Translational (BEST) Researchers
Seth Tomchik	Neuroscience & Pharmacology	NIH R01 1 year	Mechanisms of Nf1 Pathophysiology Underlying Hyperactivity
Ergun Uc, Contact PI Nandakumar Narayanan, MPI Soura Dasgupta, MPI	Neurology, Electrical & Computer Engineering	NIH RF1 3 years	Linear predictive coding of EEG Activity for Diagnosis of Parkinson's Disease (LEAD-PD)
Competitive Awards:
Bruce Gantz	Otolaryngology	NIH P50 5 years	Iowa Cochlear Implant Clinical Research Center VIII
Other Awards:
Chandrikha Chandrasekharan	Internal Medicine	Pharmaceutical Research Associates 3 years	A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated...
Alicia Gerke	Internal Medicine	Merck Sharp & Doheme LLC 3 years	INSIGNIA-COPD
Marlan Hansen	Otolaryngology	Akouos, Inc 3 years	A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations
Tahaunty Pena	Internal Medicine	Renovion, Inc. 3 years	A Phase 3 Open-Label, Randomized, Standard of Care-controlled Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants with Bilateral Lung Tr
Andrea Swenson	Neurology	Massachusetts General Hospital 3 years	HEALEY ALS Platform Trial, Task 12
Michael Tomasson	Internal Medicine	Pfizer, Inc. 3 years	A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Douglas Van Daele	Otolaryngology	Nyxoah SA 3 years	ACCCESS Study - A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate.
Patricia Winokur	Internal Medicine	Pfizer, Inc 3 years	A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE
April 2023 New Federal Awards:
Mahmoud Abou Alaiwa	Internal Medicine	NIH R01 5 years	Contribution of Small Airways to Mucociliary Transport Dysfunction
Hillel Haim	Microbiology	NIH R01 4 years	Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV
Vincent Magnotta	Radiology	NIH S10 1 year	University of Iowa - 7T Small Animal MRI Upgrade
Robert Roghair	Pediatrics	NIH R01 5 years	Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study
Robert Roghair	Pediatrics	NIH T35 5 years	Iowa Medical Student Summer Research Program in trans-NIDDK Research
Seth Tomchik	Neuroscience & Pharmacology	NIH R01 4 years	Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism
Aislinn Williams	Psychiatry	Dod, CDMRP 3 years	AR220030_Validating tRNA viruses to target SCN2A-related autism phenotypes
Competitive Awards:
Tarah Colaizy	Pediatrics	NIH UG1 7 years	NICHD Cooperative Multicenter Neonatal Research Network
Peggy Nopoulos, Contact PI John Wemmie, MPI	Psychiatry	NIH T32 5 years	The Iowa Neuroscience Specialty Program in Research Education (INSPIRE)
Patrick Sinn	Pediatrics	NIH R01 4 years	Life-long phenotypic correction of CF airways
Other Awards:
Sabarish Ayyappan	Internal Medicine	Kite Pharma, Inc. 5 years	A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25)
Chandrikha Chandrasekharan	Internal Medicine	Pfizer, Inc. 3 years	A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE
Umar Farooq	Internal Medicine	Kure.ai 3 years	CASE2422 A phase 1 single arm, open label study to evaluate the safety of UF-KURE19 cells in patients with relapsed or refractory B cell non-Hodgkin lymphomas.
Muhammad Furqan	Internal Medicine	AstraZeneca Pharmaceuticals LP 3 years	A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line
Steven Lentz	Internal Medicine	Novo Nordisk, Inc 3 years	Frontier 4
Steven Lentz	Internal Medicine	Novartis Pharmaceuticals Corporation 3 years	A PHASE 1B, OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303 IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
Janet Pollard	Radiology	Novartis Pharmaceuticals Corporation 3 years	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate
Erin Shriver	Opthalmology	Viridian Therapeutics, Inc 3 years	A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, A Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED)
March 2023 New Federal Awards:
Zuhair Ballas	Internal Medicine	NIH S10 1 year	Full Spectrum Cell Sorter Flow Cytometer
Maya Evans	Psychiatry	NIH F21 1 year	Cellular and molecular investigations of striatal enlargement in prenatal stress model of neurodevelopmental risk
Marlan Hansen, Contact PI Patricia Winokur, MPI	Otolarygology, Internal Medicine	NIH UM1 7 years	University of Iowa Institute for Clinical and Translational Science
Robert Roghair	Pediatrics	NIH T35 5 years	Medical Student Summer Research Program
Maria Spies, Contact PI Michael Spies, MPI	Biochemistry & Molecular Biology, PSET	NIH R21 2 years	Natural products inhibitors targeting homology-directed DNA repair for cancer therapy
Stefan Strack	Neuroscience, Pharmacology	NIH R21 2 years	Interplay between tau and PKA condensates in ADRD
Seth Tomchik		NIH R01 5 years	Mechanisms of compartmentalized plasticity in learning and memory
Competitive Awards:
David Gordon	Pediatrics	NIH R37 2 years	Gene expression signature based screening in Ewing sarcoma
Jia Luo	Pathology	NIH R01 5 years	Endoplasmic Reticulum Stress and Alcohol neurotoxicity
David Weiss, Contact PI Regina McGrane, MPI	Mirobiology	NSF 3 years	REU Site: Microbiology at the host-pathogen interface
Other Awards:
John Bernat	Pediatrics	Sanofi US Services, Inc 3 years	A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Active-Comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) Who have Reached Therapeutic Goals w
Muhammad Furqan	Internal Medicine	Immunocore Limited 3 years	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Katherine Mathews	Pediatrics	Virginia Commonwealth University 3 years	GRASP-01-002- Defining Clinical Endpoints in Becker Muscular Dystrophy
Praveen Vikas	Internal Medicine	Pharmaceutical Research Associates 3 years	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in
Daniel Berg	Internal Medicine	Astellas Pharma Global Development, Inc 3 years	A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Panc
Tomohiro Tanaka	Internal Medicine	PPD Investigator Services, LLC 3 years	A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis
Alejandro Comellas Freymond	Internal Medicine	AstraZenica AB 3 years	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).
Antonio Sanchez	Internal Medicine	Zydus Therapeutics Inc 3 years	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis
Andrea Swenson	Neurology	Massachusetts General Hospital 3 years	HEALEY ALS Platform Trial, Task # 11
Steven Polyak	Internal Medicine	TriNetX 2 years	A Retrospective Observational Study of the Standard of Care, and Medical and Surgical Treatment Patterns in Crohn's Perianal Fistulas (CPF) in the U.S.
February 2023 New Federal Awards:
Ernesto Fuentes	Biochemistry	NIH R01 5 years	Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems
Kristin Claflin	Neuroscience & Pharmacology	NIH K01 5 years	Regulation of neuronal function by mitochondrial uncoupling
Georgina Aldridge	Neurology	NIH R01 5 years	Cortical Alpha-Synuclein in Dementia
Markus Kuehn	Ophthalmology	NIH R01 4 years	T-cell mediated RGC damage in glaucoma
Damian Krysan	Pediatrics	NIH R21 2 years	Systematic Genetic Analysis of C. albicans CNS Infection
Competitive Awards
Noah Butler	Microbiology	NIH R01 5 years	Development and function of CD4+ memory T cells during malaria
Noah Butler	Microbiology	NIH R01 5 years	Regulation of Plasmodium-specific CD4+ T cells
Richard Smith - Contact PI Carla Nester - MPI Patrick Breheny - MPI	Otolaryngology, Pediatrics, and Biostatistics	NIH R01 5 years	C3 Glomerulopathy - A Collaborative Study
Alexander Bassuk	Pediatrics	NIH K12 5 years	Molecular and Cellular Research to Advance Child Health
Other Awards
Ferhaan Ahmad	Internal Medicine	Cytokinetics, Inc 3 years	SEQUOIA-HCM OLE
Stephan Arndt	Psychiatry	Northeast Iowa Behavioral Health 4 years	Evaluation project: Certified Community Behavioral Health Clinic Planning, Development, and Implementation Grant (CCBHC)
John Bernat	Pediatrics	AVROBIO, Inc 3 years	A Follow-Up Study of Subjects with Type 1 Gaucher Disease Who Previously Received AVR-RD-02
Linda Cadaret	Internal Medicine	Acceleron Pharma, Inc 3 years	SOTERIA: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Chandrikha Chandrasekharan	Internal Medince	CG Pharmaceuticals, Inc 3 years	A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemoth
Rami El Abiad	Internal Medince	AstraZenica Pharmaceuticals LP 3 years	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis
Umar Farooq	Internal Medince	PRA Health Sciences 3 years	Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta () CAR T Cell Investigational Products
Asad Javed	Internal Medince	Replimune, Inc 3 years	An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination with PD-1 Blockade in Patients with Solid Tumors
Douglas Laux	Internal Medince	Incyte Biosciences Internal S.a.r.l. 3 years	A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS 1) Recurrent/Metastatic Squamous Cell Carci
Margarida Magalhaes-Silverman	Internal Medince	Equillium, Inc. 3 years	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Varun Monga	Internal Medince	Medpace Clinical Research, LLC 3 years	A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Lama Noureddine	Internal Medince	Otsuka Pharmaceutical Development & Commercialization, Inc. 3 years	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Trial of Sibeprenlimab in the Treatment of Immunogl
Stefan Strack, Contact PI Marie Gaine, MPI	Neuroscience & Pharmacology	Eagles Autism Foundation 2 years	Primary PKA Dysregulation in Marbach-Schaaf Neurodevelopmental Syndrome
Patricia Winokur	Internal Medince	Pfizer, Inc. 3 years	A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS
January 2023 New Federal Awards:
Bao Vu	Molecular Physiology & Biophysics	NIH R21 2 Years	Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance
Brandon Davies	Biochemistry & Molecular Biology	NIH R01 5 Years	Regulation of Endothelial Lipase and HDL Metabolism by ANGPTL3
Chris Ahern, Contact PI Barry London, MPI	Molecular Physiology & Biophysics	NIH R01 4 Years	A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies
Chris Ahern	Molecular Physiology & Biophysics	NIH R35 5 Years	Chemical Biology of Voltage-Gated Cation Channels
David Stoltz	Internal Medicine	NIH T32 5 Years	Climate Change and Lung Health Training Program
Enrique Leira, Contact PI Anil Chauhan, MPI	Neurology & Internal Medicine	NIH U01 3 Years	The University of Iowa Stroke Preclinical Assessment Network to Support Translational Studies for Acute Cerebroprotection
Kevin Legge	Pathology	NIH R01 5 Years	Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus
M Washington	Biochemistry & Molecular Biology	NIH R35 5 Years	Structural and mechanistic studies of DNA bypass pathways in eukaryotes
Nikolai Artemyev	Molecular Physiology & Biophysics	NIH R01 4 Years	Molecular underpinnings of photoreceptor transcriptional regulation by CRX and NRL
Santiago Ortega Gutierrez	Neurology	NIH R03 2 Years	Novel risk stratification score for patients with acute Cerebral Venous Thrombosis
Other Awards:
Brian Link	Internal Medicine	Mayo Clinic (Prime: Genetech) 3 Years	Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers Within the LEO Cohort
Chandrikha Chandrasekharan	Internal Medicine	Pfitzer, Inc 3 Years	A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS
Christopher Strouse	Internal Medicine	ICON Clinical Research, LLC (Prime: Takeda) 3 Years	A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients with Multiple Myeloma
Douglas Hornick	Internal Medicine	AN2 Therapeutics 3 Years	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease
Frank Faraci	Internal Medicine	LeDucq Foundation 5 Years	Brain Endothelium: A Nexus for Cerebral Small Vessel Disease
Grerk Sutamtewagul	Internal Medicine	Pharmaceutical Research Associates (Prime: Gilead Sciences) 3 Years	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia
Jon Houtman	Cancer Center	American Cancer Society 3 Years	Iowa Cancer Research Experience (ICARE)
Katherine Mathews	Pediatrics	Asklepios BioPharmaceutical, Inc. 3 Years	A two-part multicenter study: a randomized, double-blind, placebo-controlled dose-escalation safety and bioavailability phase (Part 1) followed by double-blind, placebo-controlled, adaptive phase (Part 2) study to evaluate the safety and efficacy of LION-
Katherine Mathews	Pediatrics	Lexeo Theraputics 6 Years	A Phase 1/2 Study of the Safety and Efficacy of LX-2006 Gene Therapy in Friedreich's Ataxia
Michael Ohl	Internal Medicine	Iowa Department of Public Health (Prime: SAMHSA) 1 Year	The Integrated Addiction Care Coordination and Essential Support Services (iACCESS)
Muhammad Furqan	Internal Medicine	Amgen, Inc. 3 Years	A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Rami El Abiad	Internal Medicine	Celgene International II SARL LC 3 Years	A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
Saima Sharif	Internal Medicine	GlaxoSmithKline LLC 9 Years	Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers
Seth Tomchik	Neurosciences & Pharmacology	Texas A&M University (Prime: NIH) 2 Years	The role of Nf1 in sleep-dependent regulation of metabolic function
Umar Farooq	Internal Medicine	Caribou Biosciences, Inc. 3 Years	A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Varun Monga	Internal Medicine	C4 Therapeutics, Inc. 3 Years	Phase1/2 open-label multicenter study to characterize the safety and tolerability of CFT8634 in subjects with locally Advanced or Metastatic SMARCB1 perturbed cancers Including Synovial Sarcoma and SMARCB1-Deleted Solid Tumors
Xingshen Sun	Anatomy & Cell Biology	Cystic Fibrosis Foundation 3 Years	004590G222 Early life impact of CFTR modulators on the endocrine pancreas and diabetes in CF

2024

2022

Have A Question?

Ask the Office of Research

Dean's List: New Funding Awards 2023

New Funding Awards

2023

December 2023

November 2023

October 2023

September 2023

August 2023

July 2023

June 2023

May 2023

April 2023

March 2023

February 2023

January 2023

Have A Question?